Africa: South Africa, North Africa, and Central Africa.Middle East: GCC Countries, Israel, and Rest of Middle East.Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific.Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe.Latin America: Brazil, Argentina, Mexico, and Rest of Latin America.Near-term diversification will be added by this acquisition to Alexion’s commercial portfolio. acquired Portola through a tender offer and subsequent merger with Odyssey Merger Sub Inc. The acquisition includes Andexx, branded as Ondexxya, a Factor Xa inhibitor reversal medication. announced acquisition of Portola Pharmaceuticals, Inc. For instance, in May 2020, Alexion Pharmaceuticals, Inc. Increasing acquisition provides the opportunity to expand commercial range of anticoagulant reversal drugs, which is expected to drive the market growth during the forecast period. Key players operating in the global anticoagulant reversal drugs market are focusing on acquisitions and mergers, which is expected to drive the market growth. Global Anticoagulant Reversal Drugs Market Share (%) in Terms of Value, By Product Type, 2021 The global anticoagulant reversal drugs market is estimated to be valued at US$ 861.6 million in 2021 and is expected to exhibit a CAGR of 14.9 % during the forecast period (2021-2028)įigure 1. Idarucizumab and andexanet alfa, which reverse the anticoagulant effects of dabigatran and FXa inhibitors are DOAC reversal drugs.
In an emergency situation, clinicians need to attain rapid reversal of anticoagulation effects of the DOACs. DOACs are linked with lower rates of main and serious bleeding events compared with warfarin. Direct oral anticoagulants (DOACs) consists of dabigatran etexilate, a direct thrombin inhibitor, and specific inhibitors of stimulated coagulation factor X (apixaban, betrixaban, edoxaban, and rivaroxaban). The reversal medications recommended by doctors are determined by the patient's anticoagulant of choice. Anticoagulant reversal is a key step in the treatment of patients who are taking an anticoagulant and are experiencing life-threatening bleeding. When anticoagulant therapy needs to be reversed or neutralised due to bleeding problems, an overdose of anticoagulant therapy, or unexpected surgery, anticoagulant reversal drugs are required. Information and Communication Technology.
0 kommentar(er)
